Track market-moving stories before they get noisy

Helen of Troy promised $75-$85 million in Project Pegasus savings and "fuel" for growth; investors instead received a 49% EPS collapse, a $414.4 million goodwill impairment, and cumulative stock losses exceeding $38 per share Helen of Troy promised $75-$85 million in Project Pegasus savings and "fuel" for growth; investors instead received a 49% EPS collapse, a $414.4 million goodwill impairment, and cumulative stock losses exceeding $38 per share

Wall Street analysts forecast that Cleveland-Cliffs (CLF - Free Report) will report quarterly loss of -$0.18 per share in its upcoming release, pointing to a year-over-year increase of 64%. It is anticipated that revenues will amount to $5.15 billion, exhibiting an increase of 4.4% compared to the year-ago quarter.

Over the last 30 days, there has been an upward revision of 45.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

With that in mind, let's delve into the average projections of some Cleveland-Cliffs metrics that are commonly tracked and projected by analysts on Wall Street.

Based on the collective assessment of analysts, 'Revenues- Other Businesses' should arrive at $170.67 million. The estimate indicates a change of +4.7% from the prior-year quarter.

The average prediction of analysts places 'Revenues- Steelmaking' at $4.99 billion. The estimate suggests a change of +4.6% year over year.

Analysts forecast 'Revenues- Steelmaking- Stainless and electrical steel' to reach $424.94 million. The estimate suggests a change of -2.1% year over year.

The consensus among analysts is that 'Revenues- Steelmaking- Plate steel' will reach $282.19 million. The estimate indicates a change of +2.6% from the prior-year quarter.

It is projected by analysts that the 'Revenues- Steelmaking- Other' will reach $418.00 million. The estimate indicates a year-over-year change of +0.2%.

The collective assessment of analysts points to an estimated 'External Sales Volumes - Total steel Products' of 4105 thousands of tons. Compared to the present estimate, the company reported 4290 thousands of tons in the same quarter last year.

Analysts expect 'Average net selling price per net ton of steel products' to come in at $1109.49 . The estimate is in contrast to the year-ago figure of $1015.00 .

According to the collective judgment of analysts, 'Steel shipments by product - Coated steel' should come in at 1269 thousands of tons. The estimate is in contrast to the year-ago figure of 1142 thousands of tons.

The consensus estimate for 'Steel shipments by product - Plate' stands at 203 thousands of tons. The estimate compares to the year-ago value of 217 thousands of tons.

Analysts predict that the 'Steel shipments by product - Cold-rolled steel' will reach 660 thousands of tons. Compared to the current estimate, the company reported 627 thousands of tons in the same quarter of the previous year.

Analysts' assessment points toward 'Steel shipments by product - Hot-rolled steel' reaching 1787 thousands of tons. Compared to the present estimate, the company reported 1727 thousands of tons in the same quarter last year.

The combined assessment of analysts suggests that 'Steel shipments by product - Stainless and electrical steel' will likely reach 132 thousands of tons. The estimate compares to the year-ago value of 135 thousands of tons.

View all Key Company Metrics for Cleveland-Cliffs here>>>

Over the past month, shares of Cleveland-Cliffs have returned -24.4% versus the Zacks S&P 500 composite's +0.6% change. Currently, CLF carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

The $25K Day Trading Barrier is Gone

The long-standing Pattern Day Trader (PDT) rule that required many traders to maintain a $25,000 account balance is no longer standing in the way.

That means more traders can actively pursue short-term opportunities without the barrier that kept so many on the sidelines.

Now it's all about having the right strategy.

Dynamite Day Trading Signals helps you hit the ground running with up 2 options trade alerts per week, built to capture fast-moving opportunities.  

👉 Sign up now to receive the next trade

In the news release, Domino's Q2 2026 Earnings Call Rescheduled to 11 a.m. ET, issued 20-Jul-2026 by Domino's Pizza over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

Domino's Q2 2026 Earnings Call Rescheduled to 11 a.m. ET , /PRNewswire/ -- Domino's Pizza, Inc.'s (Nasdaq: DPZ) third-party webcast provider experienced technical issues this morning, on Monday, July 20. Domino's second quarter 2026 earnings call has been rescheduled.

What:   

Rescheduled Domino's Second Quarter 2026 Earnings Call

When: 

Monday, July 20 at 11 a.m. ET

Where:

U.S. and Canada: 888-596-4244

International: 646-968-2727
Conference ID: 3876618#

How:   

Dial-in via the numbers listed above

Contact:     

Greg Lemenchick, Vice President of Investor Relations & Sustainability

[email protected]

About Domino's Pizza®
Founded in 1960, Domino's Pizza is the largest pizza company in the world, with a significant business in both delivery and carryout. It ranks among the world's top public restaurant brands with a global enterprise of more than 22,500 stores in over 90 markets. Domino's had global retail sales of over $20.6 billion in the trailing four quarters ended June 14, 2026. Its system is comprised of independent franchise owners who accounted for 99% of Domino's stores as of the end of the second quarter of 2026. In the U.S., Domino's generated more than 85% of U.S. retail sales in 2025 via digital channels and has developed many innovative ordering platforms.

Order – dominos.com
Company Info – biz.dominos.com
Media Assets – media.dominos.com

Please visit our Investor Relations website at ir.dominos.com to view news, announcements, earnings releases, investor presentations and conference webcasts.

Correction: The Conference ID information has been added 

SOURCE Domino's Pizza

Domino's (DPZ) shares are moving higher even after the fast food chain served mixed earnings. Diane King Hall highlights key metrics to note in the report.

Nice (NICE - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this software company have returned +18.3%, compared to the Zacks S&P 500 composite's +0.6% change. During this period, the Zacks Internet - Software industry, which Nice falls in, has gained 9.4%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Nice is expected to post earnings of $2.63 per share for the current quarter, representing a year-over-year change of -12.6%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

For the current fiscal year, the consensus earnings estimate of $11.1 points to a change of -9.8% from the prior year. Over the last 30 days, this estimate has remained unchanged.

For the next fiscal year, the consensus earnings estimate of $12.64 indicates a change of +13.9% from what Nice is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Nice is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Nice, the consensus sales estimate of $767.17 million for the current quarter points to a year-over-year change of +5.6%. The $3.18 billion and $3.49 billion estimates for the current and next fiscal years indicate changes of +7.9% and +9.7%, respectively.

Last Reported Results and Surprise HistoryNice reported revenues of $768.62 million in the last reported quarter, representing a year-over-year change of +9.8%. EPS of $2.64 for the same period compares with $2.87 a year ago.

Compared to the Zacks Consensus Estimate of $761.09 million, the reported revenues represent a surprise of +0.99%. The EPS surprise was +4.76%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Nice is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Nice. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Hledat v komentářích

Investiční doporučení

Výsledky společností - ČR

Výsledky společností - Svět

IPO, M&A

Týdenní přehledy

Detail - články  

20.07.2026 16:35, aktualizováno: 20.7. 16:36

Aktualizováno

Tematicky se na finančních trzích stále točíme kolem technologií a Íránu. Co se týče problému na Blízkém východě, momentálně to vypadá, že USA a Írán jsou na cestě k další eskalaci, zatímco návrat k jednacímu stolu, natož obnovení memoranda o porozumění není pravděpodobné.

Pokračování článku je dostupné jen klientům placených služeb Patria Plus / Investor Plus případně uživatelům platformy Patria Direct. Pokud jste klientem těchto služeb, potom je nutné se Přihlásit.

V rámci placeného informačního servisu získáte přístup ke kompletnímu zpravodajství www.patria.cz bez jakýchkoliv omezení. Veškeré zprávy, komentáře a horké zprávy jsou zobrazovány terminálovou metodou (bez nutnosti obnovovat stránku) bez zpoždění a v plné verzi.

Nejen zpravodajství, ale i další služby získáte v Patria Plus / Investor Plus - sms a e-mailové zpravodajství, data z finančních trhů v reálném čase, kompletní analytický servis, rozsáhlé databáze časových řad ke stažení, prognózy vývoje a valuace, ekonomické fundamenty, nástroje a kalkulátory... více

Tagy: Google, USA, írán, Alphabet, umělá inteligence, Tesla, AI, Čína, donald trump, ecb, big tech, hormuz
Reklama

Na tomto místě můžete zahájit diskusi. Zatím nebyl zadán žádný názor. Do diskuse mohou přispívat pouze přihlášení uživatelé (Přihlásit). Pokud nemáte účet, na který byste se mohli přihlásit, registrujte se zde.

Aktuální komentáře

20.07.2026 16:35PODCAST Týdenní výhled: Výdaje a cloud Alphabetu pod drobnohledem, důležitost výsledků ServiceNow   16:04Nový britský premiér Andy Burnham slíbil nový začátek. Chce vrátit stabilitu i důvěru voličů 15:09Čínský Moonshot AI míří na burzu. Jeho model Kimi K3 znovu rozvířil debatu o budoucnosti AI   12:29Netflix jako nákupní příležitost? 11:05Mírně pozitivní start týdne. V hledáčku zůstává osud polovodičů, Írán a výsledky   10:15Bitcoinová ETF hlásí druhý týden přílivu kapitálu. Trh podle investorů hledá dno 9:24Ryanairu kvůli konfliktu na Blízkém východě klesl čtvrtletní zisk o třetinu 8:58Rozbřesk: Německo se nabízí investorům. Kdo mu uvěří? 8:52Ropa nad 90 dolary a slabší výsledky Ryanairu zhoršují náladu na trzích   6:00Trump a Pelosiová sázejí na 10 stejných akcií. Prim hrají technologičtí giganti 19.07.2026 6:11Všechny dobré nápady míří do USA 18.07.2026 6:06Komoditizace umělé inteligence a ekonomika tvaru K 17.07.2026 22:01Strach z přehnaně vysokých valuací kvůli AI přinesl na Wall Street další výprodej   18:11Nebezpečné bezpečné přístavy a nesouvisející souvislost 15:27Diverzifikace mimo AI? Těchto deset akcií má podle UBS výrazný růstový potenciál   13:43Investoři rekordně navyšují páku. Podobné tempo předcházelo tržním vrcholům 13:23Evropská komise ustupuje průmyslu. Emisní povolenky mají zůstat i po roce 2040 12:17Netflix naráží na pomalejší růst. Akcie odepisují přes 9 %   11:55Perly týdne: Omezený potenciál pro růst dolaru a vytrácející se AI nadšení 9:02Rozbřesk: Cenové stropy končí, benzín a nafta zdraží. Prodlužovat regulace ale nedává smysl
Reklama

Související komentáře

Nejčtenější zprávy dne

Nejčtenější zprávy týdne

Nejdiskutovanější zprávy týdne

Kalendář událostí

Nebyla nalezena žádná data

20.7.2026 16:40, BAAERBAG

Analytik Krishnendra Dubey z Barclays přistoupil ke zvýšení cílové ceny pro akcie Erste Group bank na 129 EUR (3 120,7 Kč) z původních 123 EUR (2 975,5 Kč). Investiční doporučení bylo současně zachováno na stupni „overweight“.

Akcie Erste Akcie Erste Group bank (BAAERBAG) dnes na pražské burze klesly o 0,22 % na 2 712 Kč, na RM-SYSTÉMu pak oslabují o 0,70 % na 2 710 Kč.

Zdroj: Bloomberg

Michal Šnobl
Fio banka, a.s.
Prohlášení

United Overseas Bank’s (UOB) Quek Ser Leang reports GBP/USD slipping but lacking strong downside momentum, with intraday trade expected between 1.3420 and 1.3475. The prior bullish view has faded after a break of 1.3450 support, and the pair is now seen in a 1.3385–1.3495 range. Over 1–3 months, broader supports lie at 1.3210 and 1.3160.

Pound loses momentum and consolidates"24-HOUR VIEW: We expected GBP to “trade in a range between 1.3450 and 1.3520” last Friday. We did not expect GBP to drop to 1.3427. Despite the decline, there has been no clear increase in downward momentum and the current price movements are likely part of a range-trading phase, expected to be between 1.3420 and 1.3475."

"1-3 WEEKS VIEW: We turned positive on GBP last Thursday (16 Jul, spot at 1.3540), indicating that “the renewed upward momentum suggests that GBP has resumed its advance.” We also indicated that “the level to monitor is 1.3590.” On Friday, GBP fell and broke below our ‘strong support’ level at 1.3450. The build-up in momentum has faded, and GBP has likely entered a range-trading phase between 1.3385 and 1.3495."

(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor. Know more.)

The gold market has bounced a bit during the early part of the trading session on Monday, as we continue to see the death cross loom large. At this point in time, the market still watches several things at once.

Gold Technical Analysis

Gold is consolidating just above $4,000, below both EMAs, after retreating from its highs. Source: TradingView. The gold market has bounced a bit during the early part of the trading session on Monday, as the $4,000 level is psychologically and structurally important at the moment. Buyers come back in despite the fact that interest rates have crept up a little bit higher during the trading session in the United States, but nothing major. The $4,000 level, I think, is a scene that a lot of people are watching very closely. It makes a lot of sense, and it is good for headlines.

We have had the Death Cross recently, where the 50-day EMA breaks down below the 200-day EMA, but that makes for good headlines. This is a situation that sometimes ends up being a bit late, so I always keep that in mind as well.

Geopolitical Drivers and Downside Risks The market right now is more or less paying close attention to what’s going on in the Middle East and trying to discern whether or not traders are going to continue to see this as an area that matters. This is a market that has a lot of noise, and I don’t see that changing in the current environment.

If the market were to break down below the $3,900 level, it would be a breach of a fresh new low, and history suggests that the next potential market memory spot is somewhere near the $3,500 level. If the US dollar continues to strengthen, that very well could be the case, but do keep in mind that both can rise. It doesn’t have to be a situation where a higher dollar means lower gold.

If you’d like to know more about how to trade gold and silver, please visit our educational area.

48.88K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVDA, AMD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

On July 20, 2026, we take a closer look at the DCF analysis for The Toronto-Dominion Bank (TD), which has shown impressive price performance over the past year,

Aptiv PLC (APTV - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this company have returned -9.8% over the past month versus the Zacks S&P 500 composite's +0.6% change. The Zacks Technology Services industry, to which APTIV PLC belongs, has lost 5.7% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

APTIV PLC is expected to post earnings of $1.42 per share for the current quarter, representing a year-over-year change of -33%. Over the last 30 days, the Zacks Consensus Estimate has changed -1.2%.

The consensus earnings estimate of $5.93 for the current fiscal year indicates a year-over-year change of -24.2%. This estimate has changed -6.9% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $7 indicates a change of +18% from what APTIV PLC is expected to report a year ago. Over the past month, the estimate has changed -0.1%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, APTIV PLC is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of APTIV PLC, the consensus sales estimate of $3.32 billion for the current quarter points to a year-over-year change of -36.3%. The $12.94 billion and $13.94 billion estimates for the current and next fiscal years indicate changes of -36.6% and +7.7%, respectively.

Last Reported Results and Surprise HistoryAPTIV PLC reported revenues of $5.09 billion in the last reported quarter, representing a year-over-year change of +5.4%. EPS of $1.71 for the same period compares with $1.69 a year ago.

Compared to the Zacks Consensus Estimate of $5.02 billion, the reported revenues represent a surprise of +1.27%. The EPS surprise was +5.56%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

APTIV PLC is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about APTIV PLC. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Tractor Supply Company (NASDAQ: TSCO), the largest rural lifestyle retailer in the United States, and the Tractor Supply Company Foundation announced today a $100,000 donation to the Farmer Veteran Coalition's (FVC) Fellowship Fund, a small grant program that provides direct assistance to veterans who are in their beginning years of farming or ranching. This marks the eighth year of this partnership, benefiting more than 450 veterans in their agricultural vent.

IREN stock was gaining alongside Hut 8 as both companies announced big cloud-computing deals.

The $25K Day Trading Barrier is Gone

The long-standing Pattern Day Trader (PDT) rule that required many traders to maintain a $25,000 account balance is no longer standing in the way.

That means more traders can actively pursue short-term opportunities without the barrier that kept so many on the sidelines.

Now it's all about having the right strategy.

Dynamite Day Trading Signals helps you hit the ground running with up 2 options trade alerts per week, built to capture fast-moving opportunities.  

👉 Sign up now to receive the next trade

July 20, 2026 08:00 ET  | Source: Harrow, Inc.

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumabIn treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11 INCHEON, Korea and NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, presented interim data from a post-marketing surveillance (PMS) study on SB11 (US brand name: BYOOVIZ®, Korea brand name: AMELIVU®), a biosimilar referencing Lucentis1, at the 44th Annual Meeting of the American Society of Retina Specialists (ASRS), held in Montréal, Canada, July 15–18, 2026.

“The interim results from this large-scale post-marketing surveillance study reinforce the comparable safety profile of SB11 to reference ranibizumab. Importantly, the study demonstrated clinically meaningful efficacy improvement in treatment-naïve patients while maintaining efficacy in those switched from other anti-VEGF therapies,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division, Samsung Bioepis. "At Samsung Bioepis, we are committed to generating robust real-world evidence that can support retinal specialists in making informed treatment decisions for their patients."

"We believe this post-marketing surveillance data further strengthens the clinical foundation supporting BYOOVIZ, reinforcing the confidence retina specialists can have in this biosimilar option — both in treatment-naïve patients and those transitioning from other anti-VEGF therapies," said Mark L. Baum, Chief Executive Officer of Harrow. "We're grateful for our collaboration with Samsung Bioepis in generating this evidence, and we remain committed to giving physicians the data they need to prescribe with confidence."

This open-label, prospective, multicenter, observational, Phase 4 PMS study, initiated in May 2022 and completed in May 2026, was designed to evaluate real-world safety and efficacy data for SB11 by evaluating a large patient population from a PMS study conducted in Republic of Korea. The interim report includes data from 298 patients (182 treatment-naïve, 116 switched) out of 305 patients who had been enrolled in the study as of the interim data cutoff. To reflect real-world practice, treatment interval was determined at the investigator’s discretion, and the study followed up with patients up to 24 weeks after the first dose. Efficacy was assessed by best-corrected visual acuity (BCVA) and central subfield thickness (CST), with subgroup analyses by treatment status (naïve/switched). Safety was evaluated by the incidence of adverse events.

The mean (standard deviation; SD) BCVA improved by -0.10 (0.29) in the treatment-naïve patients and -0.03 (0.24) in switched patients (P= 0.0239). Mean (SD) CST improved by -95 (125) µm in the treatment-naïve patients and -53 (108) µm in switched patients (P= 0.0168). Across different indications, there was no statistically significant difference in BCVA (P=0.6312) and CST (P=0.1686) outcome. In contrast, disease duration was significantly associated with BCVA (P= 0.0003) and CST (P=0.001) outcomes, suggesting that earlier treatment may lead to a better visual prognosis. No new safety concerns were identified.

Title: Efficacy and Safety of SB11 in Treatment-Naïve and Switched Patients with Retinal Diseases: Interim Results from a Post-Marketing Surveillance Study
Authors: Hyun Seung Yang, Se Joon Woo, Christopher Seungkyu Lee, Hyung-Il Kim, Kyu-Seop Kim, Kwan Hyuk Cho, Kwang Soo Kim, Inkyung Oh, Mercy Yeeun Kim, Juntae Kim, Daniel Duck-Jin Hwang
Presentation Type: paper on demand (Category: POD 1: AMD – Neovascular)

About BYOOVIZ

BYOOVIZ (ranibizumab-nuna) injection, for intravitreal use is a biosimilar to LUCENTIS (ranibizumab injection) 

INDICATIONS AND USAGE 

BYOOVIZ, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:  

Neovascular (Wet) Age-Related Macular Degeneration (AMD)  Macular Edema Following Retinal Vein Occlusion (RVO)  Myopic Choroidal Neovascularization (mCNV)    IMPORTANT SAFETY INFORMATION 

 CONTRAINDICATIONS 

Ocular or periocular infections  Hypersensitivity 
   WARNINGS AND PRECAUTIONS

Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injection  Increases in intraocular pressure (IOP) have been noted both pre- and post intravitreal injection   There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors   ADVERSE REACTIONS 

The most common adverse reactions (reported more frequently in ranibizumab treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP   Please see full Prescribing information

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

MEDIA CONTACT – Samsung Bioepis
Anna Nayun Kim, [email protected]
Yoon Kim, [email protected]

MEDIA CONTACT – Harrow
Mike Biega
Vice President of Investor Relations and Communications
[email protected]
617-913-8890

1 Lucentis is a trademark of Genentech.

Andy Burnham se po převzetí funkce britského premiéra pokusil vyslat investorům i veřejnosti jasný signál kontinuity a stability v době, kdy země za posledních 10 let zažila již sedmého předsedu vlády. Ve svém prvním projevu slíbil nový politický a ekonomický směr, který má během příštích deseti let posílit konkurenceschopnost Británie a současně ulevit domácnostem od vysokých životních nákladů.

Británie musí ukázat světu, že dokáže získat zpět stabilitu. Dnes odpoledne krátce po jmenování novým britským premiérem králem Karlem III. to prohlásil Andy Burnham. Dodal, že si dobře uvědomuje, že je sedmým šéfem vlády za posledních deset let. Burnham v prvním premiérském projevu slíbil nový politický a ekonomický model.

"Nebyli jsme dost dobří a musíme být lepší," řekl Burnham, který je nyní považován za nejpopulárnějšího labouristického politika. V premiérském křesle vystřídal Keira Starmera, od něhož již minulý týden v pátek převzal vedení labouristické strany.

"Během letoška předložím nový plán pro Británii, desetiletý plán, který vytyčí cestu z místa, kde jsme dnes, tam, kde, jak věřím, chceme všichni nehledě na původ a stranickou podporu Británii mít," řekl Burnham. Zároveň slíbil, že již nyní pomůže obyvatelům Británie ulevit od vysokých nákladů na život. První opatření včetně toho, kde na ně vláda vezme peníze, chce představit již v úterý.

Labouristé v průzkumech zaostávají za protiimigrační stranou Reform UK. Vládnoucí strana dosáhla v květnu katastrofálních výsledků v místních volbách, což vytvořilo na Starmera zesílený tlak. Tomu nakonec podlehl a rezignoval, k moci se tak dostal někdejší starosta Manchesteru Burnham.

Order includes DTIM Kits that deliver integrated Detect, Track, Identify and Mitigate capability through Ondas' counter-UAS portfolio

Award reflects continued momentum for Ondas as global defense customers expand investment in counter-UAS capabilities

WEST PALM BEACH, FL / ACCESS Newswire / July 20, 2026 / Ondas Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of advanced autonomous systems and next-generation defense and security technologies and services, today announced a $6.9 million order from the Australian Department of Defence for its DTIM Single Operator Counter-sUAS Kits, secured in partnership with in country distributor HIFraser.

Figure 1 DTIM Kit by Ondas SentinelThe order was formally awarded to DZYNE Technologies ("DZYNE"), now part of Ondas. Following the acquisition of DZYNE, the counter-UAS technologies and teams are now operating within Ondas Sentinel, the Company's dedicated U.S. defense division.

Ondas DTIM Kits deliver Detect, Track, Identify and Mitigate (DTIM) capability in a compact, single-operator package, combining the proven DTI detection platform with the globally fielded Dronebuster® (DB4) handheld effector. More than 3,000 Dronebuster® units have been deployed worldwide.

Each DTIM Kit delivers:

Long range omnidirectional drone detection up to 25+ km

Remote ID and AeroScope tracking with real time threat alerts

AI and ML powered drone identification with an updated threat library

Integrated Dronebuster® (DB4) mitigation with optional PNT Attack capability

Seamless TAK display support for complete situational awareness

"Australia's investment in Ondas' DTIM Kits underscores the increasing global priority around counter-UAS readiness and the need for trusted, scalable technologies," said Eric Brock, Chairman and CEO of Ondas Inc. "This award is an important validation of our strategy to build a leading autonomous defense technology platform, combining advanced systems, operational expertise and strong international partnerships to support mission-critical security needs worldwide."

The award further supports Ondas' strategy to scale integrated defense technologies through Ondas Sentinel while expanding partnerships with allied customers worldwide.

"This order reflects the growing demand we are seeing from allied defense customers for practical, field-ready counter-UAS capabilities that can be deployed quickly and operated with confidence," said Ryan Hartman, President and CEO of Ondas Sentinel. "By bringing DZYNE's proven counter-UAS technologies into Ondas, we are strengthening our ability to deliver integrated solutions that help operators detect, track, identify and mitigate threats in increasingly complex environments."

HIFraser emphasized the importance of the capability for Australia's rapidly evolving threat environment.

"We are proud to partner with Ondas Sentinel to bring cutting-edge single-operator counter-UAS capability to Australian forces," said Debora Fortkamp, Chief Strategy Officer at HIFraser. "The DTIM Kits align directly with the needs of Australian operators in today's complex operational environment."

With production capacity already scaled, Ondas Sentinel will begin delivery of DTI systems under the contract and remains prepared to support future expansion as Australia strengthens its counter-UAS posture.

For more information on Ondas' counter-UAS portfolio, please contact [email protected].

About Ondas Inc.
Ondas Inc. (NASDAQ:ONDS) is a leading provider of autonomous systems, robotics, and mission-critical technologies for defense, homeland security, public safety, critical infrastructure, and industrial markets. The Company develops and deploys integrated unmanned and autonomous platforms across air, ground, and stratospheric environments, designed to support intelligence, surveillance, reconnaissance, security, and operational missions in complex environments. Ondas' solutions are deployed globally by government, defense, and commercial customers to protect infrastructure, borders, transportation networks, personnel, and strategic assets.

For additional information on Ondas Inc., visit www.ondas.com.

Forward-Looking Statements
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as required by law.

Contacts

IR Contact for Ondas Inc.
888-657-2377
[email protected]

Media Contact for Ondas Inc.
Escalate PR
[email protected]

Preston Grimes
Marketing Manager, Ondas Inc
[email protected]

Jill Vacek
Director of Communications, Ondas Sentinel
[email protected]

SOURCE: Ondas Inc.

© Gorodenkoff / Shutterstock.com

Shares of AI infrastructure names are bouncing hard in early Monday trading, led by IREN (NASDAQ:IREN), up 17% to $39.28. Applied Digital (NASDAQ:APLD) is up 9% to $28.06, TeraWulf (NASDAQ:WULF) is up 7% to $19.44, and Core Scientific (NASDAQ:CORZ) is up 7% to $22.31.

The moves come after a punishing stretch. IREN shares fell 42% over the past month into Friday’s close, while APLD stock slid 43%, WULF shares dropped 35%, and CORZ stock lost 26%. Today’s bounce reads as a technical recovery rather than a fresh catalyst.

A Bounce Off of Deeply Depressed Levels There is no confirmed news catalyst behind Monday’s rebound in the four former Bitcoin (CRYPTO:BTC) miners turned AI infrastructure operators. The group has been at the center of a sector-wide AI infrastructure de-rating, and each name entered the day trading well below its 50-day moving average. IREN stock, for instance, closed Friday at $33.62 versus a 50-day moving average of $52.71.

The fundamentals underneath the moves remain mixed. IREN’s Q3 FY2026 revenue came in at $144.8 million, well short of the roughly $219.3 million analyst estimate, with a net loss of $247.8 million. The bull case rests on a 5-year, $3.4 billion AI Cloud contract with NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) and a target of 150,000 deployed GPUs by end of CY2026.

Applied Digital told a different story. Its Q3 FY2026 revenue rose 139% year over year to $126.6 million, with adjusted EBITDA of $44.1 million. Applied Digital CEO Wes Cummins noted that hyperscaler annual capex reportedly grew from roughly $400 billion to nearly $700 billion, with anchor customer CoreWeave (NASDAQ:CRWV) driving Polaris Forge demand.

Sector Context and Peer Reaction TeraWulf and Core Scientific are riding similar structural tailwinds. TeraWulf’s HPC lease revenue reached $21 million in Q1 FY2026, over 60% of total revenue, backed by anchor tenants including an Alphabet‘s (NASDAQ:GOOGL) Google credit-supported financing package. Core Scientific posted 45% year-over-year revenue growth to $115.2 million, with high-density colocation surging 9x YoY.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Iren didn't make the cut. Grab the names FREE today.

The Global X Data Center & Digital Infrastructure ETF (NASDAQ:DTCR) offers a lower-volatility angle on the same theme, and it’s up 2% to $27.91 in early Monday trading. The ETF holds Applied Digital at only 3.2% and doesn’t hold IREN, CORZ, or WULF. Instead, its top positions are data center REITs like Equinix (NASDAQ:EQIX), Digital Realty Trust (NYSE:DLR), and American Tower (NYSE:AMT), plus chip names including Broadcom (NASDAQ:AVGO) and Marvell Technology (NASDAQ:MRVL).

Retail sentiment tells a more cautious story. StockTwits’s AI sentiment summary suggests the community is divided, with bulls citing AI cloud demand and a raised ARR target and bears pointing to share dilution and management compensation concerns. Separately, Reddit chatter on IREN skewed bearish to very bearish across the past week.

What to Watch Now All four names remain unprofitable on a trailing basis, and each carries a high beta (IREN’s beta sits at 4.279, CORZ at 5.5). Investors can watch for whether today’s bounce holds through the close and whether volume confirms the reversal.

The next fundamental catalyst is earnings season, when hyperscaler capex commentary from Microsoft (NASDAQ:MSFT) and its peers can reset the trajectory for this cohort. Until then, price action in this sector will likely be dictated by positioning and sentiment rather than fresh operating data.

The takeaway: Monday’s rebound appears to be a technical relief rally off deeply oversold levels, not a confirmed change in trend. The fundamentals remain bifurcated (Applied Digital and Core Scientific are showing operating leverage, while IREN and TeraWulf still carry heavier losses), and investors should treat the bounce accordingly.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Iren didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Futu Holdings Limited (NASDAQ: FUTU) ("Futu" or the "Company") on behalf of investors who purchased or acquired Futu securities during the period from May 24, 2023 through May 27, 2026 (the "Class Period").

Investor Deadline: Investors who purchased or acquired Futu securities during the Class Period may, no later than August 25, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

Headquartered in Hong Kong, Futu is an online brokerage and wealth management company that provides securities trading, investment, and financial services to retail investors.

According to the complaint, throughout the Class Period, Defendants failed to disclose that certain Futu entities allegedly conducted securities business, public fund sales business, and futures business in mainland China without obtaining the required regulatory approvals. The complaint further alleges that, on December 30, 2022, the China Securities Regulatory Commission ("CSRC") stated that Futu had conducted cross-border securities business with domestic investors in mainland China without regulatory consent, resulting in restrictions on opening new accounts for mainland Chinese investors and soliciting new business from mainland investors.

The truth allegedly began to emerge on May 22, 2026, when Reuters reported that the CSRC, together with seven other Chinese government agencies, had launched a regulatory crackdown targeting brokers allegedly operating without approval. That same day, Futu disclosed that it had received a Notification Letter from the CSRC imposing approximately RMB1.85 billion (approximately US$271 million) in confiscation of alleged illegal gains and fines, as well as a proposed personal fine against the Company's founder and Chief Executive Officer, Li Hua. Following these disclosures, Futu's stock price fell $34.10 per share, or 27.5%, to close at $89.76 on May 22, 2026.

The truth allegedly continued to emerge on May 28, 2026, when Futu reported first-quarter 2026 financial results reflecting the proposed regulatory penalties, including approximately RMB470 million in confiscated alleged illegal gains and approximately RMB1.38 billion in fines. Following this disclosure, the Company's stock price fell an additional $5.31 per share, or 4.8%, to close at $104.91.

If you are a Futu investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267) 764-4865.

About Berger Montague

Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

For more information or to discuss your rights, please contact:

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305719

Source: Berger Montague

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

The $25K Day Trading Barrier is Gone

The long-standing Pattern Day Trader (PDT) rule that required many traders to maintain a $25,000 account balance is no longer standing in the way.

That means more traders can actively pursue short-term opportunities without the barrier that kept so many on the sidelines.

Now it's all about having the right strategy.

Dynamite Day Trading Signals helps you hit the ground running with up 2 options trade alerts per week, built to capture fast-moving opportunities.  

👉 Sign up now to receive the next trade

983 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Meta Platforms is leveraging AI capex to drive both internal ad growth and new external monetization opportunities. META is negotiating a $10 billion, two-year AI compute deal with Anthropic, signaling a shift toward AI cloud revenue streams. Even modest external AI cloud deals could provide significant EPS upside, with $20 billion in AI cloud revenue equating to a $5+ EPS boost.

Tesla reports second quarter earnings on Wednesday and Elon Musk is teasing more technology improvements.